Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Flanigan J, Deshpande H, Gettinger S. Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics: Targets And Therapy 2010, Volume 4: 237-243. PMID: 20859451, PMCID: PMC2943196, DOI: 10.2147/btt.s7223.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerEpidermal growth factor receptorLung cancerClinical trialsAdvanced non-small cell lung cancerPhase II clinical trial dataRandomized phase III trialOral small-molecule inhibitorNSCLC clinical trialsPhase III trialsGrowth factor receptor 2Vascular endothelial growth factor receptor 2Endothelial growth factor receptor 2Clinical trial dataFactor receptor 2Growth factor receptorOral agentsIII trialsDaily doseMultiple malignanciesReceptor 2Small molecule inhibitorsUS FoodDrug Administration